MET and hepatocellular carcinoma: Similarly, analysis of an unselected cohort of participants with advanced HCC in a phase II trial of the MET inhibitor tivantinib, showed no significant difference between placebo and drug-treated individuals; however, once patients were stratified into MET-high and MET-low groups, a positive difference in response was observed in the MET-high group [41].